Central Garden & Pet heads into the final week of August with a sharp and accelerating build in short positions, options traders at their most defensive all year, and a stock that has barely moved — a combination that makes the positioning story the most compelling angle right now.
The short interest rebuild is striking in its pace. Shares short have risen 48% over the past week alone, and are up roughly 33% over the past month, reaching around 521,000 shares as of August 27. To put the pace in context: the position was relatively stable through most of July and early August around 275,000–280,000 shares, before beginning a steady climb in mid-August that has sharply accelerated this week. Days-to-cover from the most recent official FINRA data sits at 3.04 days — not extreme, but enough to give any squeeze scenario some teeth if sentiment were to reverse. The ORTEX short score has climbed from 44.1 on August 14 to 57.6 by August 27, its highest reading in the available history and rising every single session over that stretch.
Options positioning reinforces the caution. The put/call ratio has jumped to 3.35 — the highest level of the past year and nearly two standard deviations above its 20-day average of 2.22. That's an unusual degree of skew toward downside protection, even for a name that has historically carried a defensive bias. The borrow market, by contrast, looks loose. Availability is running at roughly 223% of short interest, meaning there are more than two shares available to borrow for every one already shorted. Borrow costs have ticked up — cost-to-borrow has risen 56% over the past week to 0.87% — but that remains firmly in the low-cost range. So the short build is happening in conditions where lenders are accommodating, not in a stressed borrow environment.
The Street is broadly constructive but not recently vocal. Analyst data is slightly stale — the most recent change logged was Canaccord Genuity raising its target to $54 in early May, keeping a Buy rating after the August earnings beat that sent the stock up 5.6% on the day. Coverage is thin, concentrated largely at Canaccord and Truist, both at Buy with targets in the $53–54 range against a current price of $43.70 — implying roughly 21% upside on the consensus. Valuation looks undemanding: the stock trades at about 11.4x trailing earnings and 7x EV/EBITDA, with a price-to-book of 1.12. The ORTEX short score rank of 17 (out of 100) and a sector score at the 50th percentile suggest the stock is not especially flagged by systematic models — which makes the manual short build more interesting, not less.
Institutional ownership is stable and concentrated at the top. BlackRock holds 16% of shares, with Vanguard and Dimensional each around 6%, and American Century adding over 457,000 shares in the most recent reported period. The insider picture is dormant — the most recent logged trade is from February 2025, too stale to carry weight here.
Peer context adds some texture. CHD (Church & Dwight) rose 5.1% on the week, while REYN (Reynolds Consumer) fell 5.1% and CLX (Clorox) dropped 2.3%. CENT's roughly flat week — down just 0.6% — sits in the middle of a mixed peer tape, giving the short build no obvious macro-sector catalyst to point to.
The next scheduled earnings date is late November, leaving an extended window before the next fundamental catalyst. What to watch is whether the short build continues to accelerate at the current pace, or whether the abundance of available shares to borrow tempts covering before any identifiable trigger appears.
See the live data behind this article on ORTEX.
Open CENT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
